Details for New Drug Application (NDA): 007883
✉ Email this page to a colleague
NDA 007883 describes ANTABUSE, which is a drug marketed by Odyssey Pharms and Teva Womens and is included in three NDAs. Additional details are available on the ANTABUSE profile page.
The generic ingredient in ANTABUSE is disulfiram. There are seven drug master file entries for this compound. Four suppliers are listed for this compound. Additional details are available on the disulfiram profile page.
The generic ingredient in ANTABUSE is disulfiram. There are seven drug master file entries for this compound. Four suppliers are listed for this compound. Additional details are available on the disulfiram profile page.
Summary for 007883
| Tradename: | ANTABUSE |
| Applicant: | Teva Womens |
| Ingredient: | disulfiram |
| Patents: | 0 |
Medical Subject Heading (MeSH) Categories for 007883
Profile for product number 002
| Active Rx/OTC/Discontinued: | DISCN | Dosage: | TABLET;ORAL | Strength | 500MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** | ||||
| Approval Date: | Approved Prior to Jan 1, 1982 | TE: | RLD: | Yes | |||||
Profile for product number 003
| Active Rx/OTC/Discontinued: | DISCN | Dosage: | TABLET;ORAL | Strength | 250MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** | ||||
| Approval Date: | Approved Prior to Jan 1, 1982 | TE: | RLD: | Yes | |||||
Complete Access Available with Subscription
